Selegiline-citalopram combination in patients with Parkinson's disease and major depression.
We evaluated the efficacy and safety of the selegiline citalopram combination in the treatment of major depression in patients with Parkinson's disease. Eight consecutive depressed outpatients who had received previously selegiline monotherapy or (one patient) selegiline-levodopa combination (the dose of selegiline was 5-10 mg/day in each case) for mild to severe Parkinson's disease were treated with 20 mg citalopram/day. The severity of depression was evaluated on the Hamilton Depression Rating Scale before and 8 weeks after citalopram treatment. The majority of the patients (six) responded well to citalopram treatment and no adverse events occurred. The combination of a low dose of selegiline (5-10 mg daily) and citalopram (20 mg daily) may be an effective and safe method in the treatment of major depression in patients with Parkinson's disease. (Int J Psych Clin Pract 2000; 4:123-125).